Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Safety and Efficacy of Different Doses of Intravenous APD405 for the Prevention of Post-Operative Nausea and Vomiting.

Trial Profile

Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Safety and Efficacy of Different Doses of Intravenous APD405 for the Prevention of Post-Operative Nausea and Vomiting.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2013

At a glance

  • Drugs APD 405 (Primary)
  • Indications Postoperative nausea and vomiting
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Apr 2012 Planned number of patients changed from 260 to 282 as reported by European Clinical Trials Database record.
    • 24 Dec 2009 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
    • 24 Dec 2009 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top